Questionnaire

1. The GINA treatment guidelines and South African asthma guidelines recommend that optimal care for all adolescents and adults with asthma should be:

2. Asthma due to a type 2 allergic response is triggered by:

3. In non-eosinophilic Th2low asthma, the immune response may typically be driven by:

4. Non-eosinophilic Th2low asthma is often associated with:

5. Benralizumab is a biologic therapy targeted towards:

6. Which of these monoclonal antibodies is administered as an intravenous infusion?

7. A biomarker that is commonly used to help guide therapeutic choice of biologic therapy in a patient with asthma is:

8. Which of the following is predictive of a better response to benralizumab in a patient with asthma?

9. After the first three doses, benralizumab is administered every:

10. Depending on the biologic in question and patient characteristics, in clinical trials of biologic therapy, outcomes included significant reductions in:

11. In a review of the Danish Severe Asthma Register including all adult patients receiving biologic therapy for severe asthma in Denmark, the percentage of previously biologic-naive patients who had a clinical response within 12 months of starting the biologic was:

12. A patient with well-controlled asthma will not use their reliever medication (e.g. SABA) more than:

13. The ‘severity’ of asthma is a retrospective diagnosis, because it can only be assessed after several months of optimised therapy and stepping down to find the minimum effective treatment regimen that will control the patient’s symptoms:

14. In a patient with asthma, low FEV1 (especially <60% predicted) and high bronchodilator responsiveness indicates increased risk for exacerbations:

15. In a comprehensive clinical trial programme, over a period of approximately six months, in patients with severe, uncontrolled asthma receiving benralizumab, the exacerbation rate was reduced by approximately 50-70%, with clinical benefits observed within the first 1-4 weeks of treatment: